Search

Displaying results 1061 - 1070 of 7058 in total
  1. Drug

    Rozanolixizumab

    go.drugbank.com/drugs/DB14919
    ApprovedInvestigational

    Rozanolixizumab-noli is available under the brand name RYSTIGGO and was developed by UCB. … [L47122] It was granted orphan drug designation by the FDA in 2019, by the European Medicines Agency (EMA) in April 2020, and by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) in November

  2. Drug

    Atezolizumab

    go.drugbank.com/drugs/DB11595
    ApprovedInvestigational

    [L7489] Atezolizumab was granted FDA approval on 18 October 2016. … [A18493,L7489] This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum-based chemotherapy, or whose tumors do not respond to platinum-based chemotherapy.

  3. Target

    Cytosolic non-specific dipeptidase

    go.drugbank.com/bio_entities/BE0018303
    EnzymeHumans

    Cytosolic metallodipeptidase with broad substrate specificity that catalyzes the hydrolysis of amide bonds in dipeptides and pseudopeptides (PubMed:12473676, PubMed:19346245, PubMed:25964343). Substrates include L-cysteinylglycine, an in...

    Synonyms: PEPA
  4. Drug

    Candesartan cilexetil

    go.drugbank.com/drugs/DB00796
    ApprovedInvestigational

    Unlike angiotensin-converting enzyme (ACE) inhibitors, ARBs do not have the adverse effect of dry cough.

    Mixtures: CANDESARTAN PL 1A 32/25, CANDESARTAN PL 1A 32/25Products: Candesartan A-med 8 mg Tabletten, Candesartan A-med 16 mg Tabletten
  5. Drug

    Midazolam

    go.drugbank.com/drugs/DB00683
    ApprovedIllicitInvestigational

    [F2977] This drug was initially approved by the US FDA in 1985, and has been approved for various indications since. … [L45098] In late 2018, the intramuscular preparation was approved by the FDA for the treatment of status epilepticus in adults.

    Products: N/a
  6. Drug

    Fencamfamin

    go.drugbank.com/drugs/DB01463
    ApprovedIllicitWithdrawn

    Fencamfamin (Glucoenergan, Reactivan) is a stimulant which was developed in the 1960s as an appetite suppressant. … Fencamfamin is used for treating depressive day-time fatigue, lack of concentration and lethargy. It is especially useful in patients with chronic conditions due to its favourable safety profile.

  7. Drug

    Ripasudil

    go.drugbank.com/drugs/DB13165
    Investigational

    This medication is available in the form of a 0.4% eye drop solution under the brand name Glanatec. … Ripasudil is a well tolerated medication that is used when other drugs have been proven to be non-effective or cannot be administered.

  8. Drug

    Cobamamide

    go.drugbank.com/drugs/DB11191
    ApprovedNutraceutical

    This drug is available as a nutritional supplement to prevent vitamin B12 deficiency. Vitamin B12 is a collective term for these variously substituted corrinoids. … Vitamin B12 has important physiological roles including DNA synthesis, myelin formation in the nervous system, red blood cell formation, as well as fatty acid and amino acid metabolism [L2047].

    Mixtures: BumP DHA, BumP DHA
  9. Drug

    Levoleucovorin

    go.drugbank.com/drugs/DB11596
    ApprovedInvestigational

    As methotrexate functions as a DHFR inhibitor to prevent DNA synthesis in rapidly dividing cells, it also prevents the formation of DHF and THF. … This results in a deficiency of coenzymes and a resultant buildup of toxic substances that are responsible for numerous adverse side effects of methotrexate therapy.

    Categories: Compounds used in a research, industrial, or household settingProducts: CALCIO LEVOFOLINATO TEVA GENERICS
  10. Drug

    Pariglasgene brecaparvovec

    go.drugbank.com/drugs/DB16801
    Approved

    [L64050] The FDA granted pariglasgene brecaparvovec-opnr accelerated approval on August 19, 2026, making it the first approved treatment for glycogen storage disease type Ia. … [L64050,L64051] It is administered as a single, one-time intravenous infusion.